Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 12;183(4):1086-1102.e23.
doi: 10.1016/j.cell.2020.09.055.

An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation

Affiliations
Free article

An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation

Juan José Bonfiglio et al. Cell. .
Free article

Abstract

Strategies for installing authentic ADP-ribosylation (ADPr) at desired positions are fundamental for creating the tools needed to explore this elusive post-translational modification (PTM) in essential cellular processes. Here, we describe a phospho-guided chemoenzymatic approach based on the Ser-ADPr writer complex for rapid, scalable preparation of a panel of pure, precisely modified peptides. Integrating this methodology with phage display technology, we have developed site-specific as well as broad-specificity antibodies to mono-ADPr. These recombinant antibodies have been selected and characterized using multiple ADP-ribosylated peptides and tested by immunoblotting and immunofluorescence for their ability to detect physiological ADPr events. Mono-ADPr proteomics and poly-to-mono comparisons at the modification site level have revealed the prevalence of mono-ADPr upon DNA damage and illustrated its dependence on PARG and ARH3. These and future tools created on our versatile chemical biology-recombinant antibody platform have broad potential to elucidate ADPr signaling pathways in health and disease.

Keywords: ADP-ribosylation; DNA damage; HFP1; MARylation; PARP1; antibodies; chemical biology; histones; mono-ADP-ribosylation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests I.M., J.J.B., and T.C. are inventors on EU patent applications PCT/EP2018/078592 and PCT/EP2019/074885 filled by the Max Planck Society and related to the technology for site-specific generation of Ser-ADP-ribosylated peptides.

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources